Last updated on June 2019

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.


Brief description of study

To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.

Clinical Study Identifier: NCT02759419

Find a site near you

Start Over

Bayer Clinical Trials Contact

Le Kremlin Bicetre Cedex, France
8.2miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.